Mitsubishi Tanabe Pharma Sustainability Profile
Mitsubishi Tanabe Pharma Corporation, often referred to as MTPC, is a prominent player in the global pharmaceutical industry, headquartered in Japan. Established in 1678, the company has evolved significantly, focusing on innovative drug development and therapeutic solutions primarily in the fields of neurology, immunology, and diabetes care. With a strong presence in Japan, North America, and Europe, Mitsubishi Tanabe Pharma is renowned for its unique core products, including treatments for multiple sclerosis and other chronic conditions. The company has achieved notable milestones, such as the successful launch of its flagship drug, which has positioned it as a leader in the biopharmaceutical market. Committed to advancing healthcare, Mitsubishi Tanabe Pharma continues to make significant contributions to patient well-being through its research and development initiatives.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mitsubishi Tanabe Pharma's reported carbon emissions
In 2023, Mitsubishi Tanabe Pharma reported total carbon emissions of approximately 768.9 million kg CO2e. This figure includes 18.7 million kg CO2e from Scope 1 emissions, 36.3 million kg CO2e from Scope 2 emissions, and 713.9 million kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 682.2 million kg CO2e. The company has set ambitious climate commitments, aiming for a 45% reduction in greenhouse gas (GHG) emissions by 2030 compared to 2019 levels, with a long-term goal of achieving net-zero emissions by 2050. These targets encompass both Scope 1 and Scope 2 emissions and are applicable to all domestic and overseas group companies. Mitsubishi Tanabe Pharma's emissions data is cascaded from its parent company, Mitsubishi Tanabe Pharma Corporation, reflecting a commitment to transparency and accountability in its climate strategy. The company is actively working towards these reduction targets, demonstrating a proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 35,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 71,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 | - | 000,000,000 |
How Carbon Intensive is Mitsubishi Tanabe Pharma's Industry?
How Carbon Intensive is Mitsubishi Tanabe Pharma's Location?
Mitsubishi Tanabe Pharma's Scope 3 Categories Breakdown
Mitsubishi Tanabe Pharma's Scope 3 emissions, which increased by 14% last year and increased by approximately 33% since 2018, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 96% of Scope 3 emissions.
Top Scope 3 Categories
Mitsubishi Tanabe Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mitsubishi Tanabe Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.